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Abstract
Background: We investigated dynamic patterns and predictors of HPV vaccination initiation in Flanders (Belgium)
by girls aged 12 to 18, between 2007 and 2009, the period immediately after the introduction of the HPV vaccines
on the Belgian market. During this period the initiative for vaccination was taken by the girl, her family or the
general practitioner/pediatrician/gynecologist.
Methods: We used a Cox regression model with time constant and time varying predictors to model hazard rates
of HPV vaccination initiation. The sample existed of 117,151 female members of the National Alliance of Christian
Mutualities, the largest sickness fund in Flanders.
Results: The study showed that the hazard of HPV vaccination initiation was higher (1) for older girls, (2) for girls
with a more favorable socio-economic background, (3) under more generous reimbursement regimes (with this
effect being more pronounced for girls with weak socioeconomic backgrounds), (4) for girls that were informed
personally about the reimbursement rules.
Conclusions: When the initiative for HPV vaccination lies with the girls, their families or the physicians (no
organized setting) the uptake of the vaccines is affected by both individual and organizational factors.
Background
On May 2
nd 2007 the Belgian Superior Health Council
(SHC) made its first recommendations regarding HPV-
vaccination. It recommended, among others, that orga-
nized (i.e. school-based) HPV vaccination should be
offered each year to a one-year birth cohort of girls
aged 10, 11, 12 or 13 years [1]. In spite of these recom-
mendations, only from September 2010 on school-based
HPV vaccination was introduced in Flanders (northern
part of Belgium) for girls aged 12 years. Until then, the
initiative for vaccination lied with the girls, their families
or the physicians (general practitioners/paediatricians/
gynaecologists).
In Belgium vaccination of adolescents can take place
in- or outside the school-based vaccination system.
When vaccines are offered inside the school-based
system School Health Services are responsible for
monitoring the vaccination status of the adolescents,
collecting necessary immunization data, informing par-
ents and children and offering the recommended vacci-
nations. Parents are free to accept this offer or to get
their child vaccinated by a paediatrician, gynaecologist
or general practitioner. Vaccines offered to adolescents
within the school-based system as well as their adminis-
tration are free of charge for the vaccinee. When adoles-
cent vaccines are not incorporated in the school-based
vaccination system the initiative for vaccination lies with
the parents, adolescents or physicians. In that case, the
administration costs of the vaccines have to be paid by
the vaccinees. For some vaccines the vaccinees have to
pay the full price, for others partial reimbursement is
provided via the health insurance system. This insurance
system is compulsory and covers the entire population.
It is organized through private, non-profit sickness
funds. The two largest sickness funds are the Christian
(National Alliance of Christian Mutualities, henceforth
NACM) and the Socialist Mutualities, together insuring
about 75% of the population [2]. Two reimbursement
* Correspondence: eva.lefevere@ua.ac.be
1Herman Deleeck Centre for Social Policy, Antwerp University, St Jacobstraat
2, 2000 Antwerpen, Belgium
Full list of author information is available at the end of the article
Lefevere et al. BMC Public Health 2011, 11:470
http://www.biomedcentral.com/1471-2458/11/470
© 2011 Lefevere et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.regimes exist. If a vaccine is included in the broad bene-
fit package of the “Compulsory insurance” it is (partly)
reimbursed by the national government and the reim-
bursement rates are identical for all sickness funds. A
vaccine can also be included in the “Supplementary
insurance” of a sickness fund (usually at a lower reim-
bursement rate than under the Compulsory insurance),
ap a c k a g eo fs u p p l e m e n t a r yi nsurance benefits that a
sickness fund is free to compose. The reimbursement
rates are established by the sickness fund itself, and only
hold for its own members.
We studied the dynamic patterns of HPV vaccination
initiation in Flanders during the first 2.5 years after the
introduction of the vaccines on the Belgian market (Jan-
uary 2007 -June 2009), so before the HPV-vaccines were
offered free of charge through the school-based vaccina-
tion system. During our period of analysis, the vaccines
were partially reimbursed by the health insurance sys-
tem. The reimbursement regime (Compulsory versus
Supplementary insurance) varied over time, mainly
depending on the age of the girls (for details see below)
and the membership of a respective sickness fund. We
used a Cox regression model with time constant and
time varying predictors to determine factors affecting
the hazard of HPV vaccination initiation.
Methods
We analyzed data from one sickness fund, the NACM,
which covers 53% of the Flemish population. All data
extractions and analyses were performed at the Medical
Management Department of the NACM under supervi-
sion of a medical advisor.
Sample
We selected girls aged 12 to 18 (years of birth 1989 to
1996) who were member of the NACM on December
31
st 2006 and who were living in Flanders (N =
151,058). We excluded girls for whom one of the pre-
dictor variables (see below) was missing (N = 7,792) and
those for whom a vaccine was reimbursed before they
had become eligible for reimbursement (N = 1,113),
assuming this to be the consequence of inaccuracies in
the data. This left us with 142,153 girls.
These 142,153 girls belonged to 117,151 families.
Because the similarity in vaccination behavior between
sisters could affect the standard errors in our analysis,
we randomly selected one girl per family to be included
in the study. In this way, the final sample consisted of
117,151 girls.
Variables
T h ed a t eo fr e i m b u r s e m e n to ft h ef i r s td o s eo faH P V -
vaccine was retrieved from the reimbursement claims of
the NACM.
Two demographic background variables (year of birth
of the girls and province of residence) were available
from the membership files of the NACM.
Two predictors reflecting the socio-economic back-
ground of the girls were the median income of the
neighborhood in which they were living (in quintiles),
and a variable indicating whether they were entitled to
preferential treatment or not. To construct the first vari-
able we used data from the Belgian Directorate-General
Statistics and Economic Information on median net tax-
able incomes per neighborhood for 2006 (based on tax
declarations). We classified each Flemish neighborhood
into 1 of 5 income quintiles, linked the address of each
girl to the neighborhood, and each neighborhood to the
corresponding income quintile. The second variable was
the right to preferential treatment. In the Belgian health
insurance, certain categories of people enjoy this “pre-
ferential treatment”,w h i c hm e a n st h e yp a yl o w e rc o -
payments. At the time of the analysis, there were two
basic grounds for preferential treatment eligibility. First,
people receiving certain social benefits (social assistance,
guaranteed income for elderly, guaranteed income for
disabled), and their partners and descendants, were
automatically entitled to preferential treatment. Second,
certain categories of people (most importantly: orphans,
widows, widowers, disabled, elderly, long term unem-
ployed, children with severe mental or physical illnesses)
and their partners and descendants were entitled to pre-
ferential treatment after an income test had shown that
their household income was below a certain threshold.
In both cases, a low household income is a direct or
indirect condition for preferential treatment. In our ana-
lysis a girl was said to have a right to preferential treat-
ment if at least someone in the family was entitled to
this preferential treatment (indicating a low household
income) on December 31
st 2006.
Another variable used in the analysis was the reimbur-
sement regime under which the vaccine was reimbursed.
The Lexis diagram (figure 1) illustrates the changes in
reimbursement regime over time. The HPV vaccines
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Figure 1 Lexis diagram illustrating different reimbursement
regimes.
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st 2006
(Gardasil
®)a n dO c t o b e r1
st 2007 (Cervarix
®). Between
November 1
st 2006 and January 1
st 2007 no reimburse-
ment was available. Since we use reimbursement data
and not sales data we do not have data on vaccination
uptake for this period. Previous research however indi-
cates that the number of vaccines sold in this period
was very small [3]. Reimbursement under the Compul-
sory insurance (red line in figure 1) was offered to girls
aged 12 to 15 from November 1
st 2007 until December
31
st 2008, and for girls aged 12 to 18 from January 1
st
2009 on. Reimbursement under the NACM Supplemen-
tary insurance was offered to girls aged 13 to 14 from
January 1
st 2007 to October 30
th 2007 and to girls aged
16 to 19 between November 1
st 2007 and December
31
st 2008 ("Supplementary insurance, strict”, yellow line
in figure 1). Until October 30
th 2007 the age criteria for
Supplementary insurance were sometimes applied flex-
ibly, so that exceptionally, when a member not meeting
the criteria asked for reimbursement, this was also
granted (in a limited number of cases) ("Supplementary
insurance, flexible”, green line in figure 1).
A final variable added to the analysis was whether or
not the girl had received an information letter on the
inclusion of HPV vaccination in the package of Compul-
sory insurance. When this measure was introduced on
November 1
st 2007, the NACM proactively informed
the girls approaching the maximum age for reimburse-
ment (girls born between November 16
th 1991 and
December 31
st 1992) on the reimbursement rules. In the
letter (sent on October 31
st 2007) objective information
about the vaccine and the reimbursement was given.
E m p h a s i sw a sp u to nt h ef a c tt h a tt h e yd i dn o th a v ea
lot of time left to get their first vaccine, since no reim-
bursement would be granted after their 16
th birthday.
Statistical methods
First, we looked at the bivariate associations between
HPV vaccination initiation and some background char-
acteristics. The significance of these associations was
assessed by means of the (two-sided) chi-square test.
For this analysis, HPV vaccination initiation was an indi-
cator denoting whether or not at least one dose of the
HPV vaccine was reimbursed to a girl during our period
of analysis.
Next, we estimated a Cox regression model with time-
constant and time-dependent covariates (SAS procedure
PROC PHREG) to model the time to HPV vaccination
initiation. HPV vaccination initiation was then the age
( i nd a y s )a tw h i c ht h ef i r s tH P Vv a c c i n ed o s ef o rag i r l
was reimbursed. It was calculated as the number of days
between the date of reimbursement of the first dose of a
HPV vaccine and the date of birth of the girl. Year of
birth of the girl, province of residence, preferential
treatment and median income of the neighborhood
where the girl was living were added as time-constant
variables. Three time-varying variables were added. The
first two indicated the reimbursement regime, with the
Compulsory insurance as the reference category and the
two other regimes (Supplementary insurance strict and
flexible) as time varying indicators taking on value 1 in
periods when the regime was in place and value 0 other-
wise. The second was the receipt of a NACM letter. For
each girl born between November 16
th 1991 and
December 31
st 1992, this variable was an indicator tak-
ing value 1 in the period from November 1
st 2007 to
the sixteenth birthday of the girl and value 0 at other
times. For the other girls in the analysis, the indicator
took on value 0 over the whole period of analysis.
Because it was possible that the cost of the vaccines and
the NACM letter had a different impact on HPV vacci-
nation initiation by people from different socio-eco-
nomic backgrounds [4,5] we added two interaction
effects: one between the type of reimbursement regime
(i.e. Supplementary insurance (flexible and strict taken
together) versus NIHDI reimbursement) and the right
to preferential treatment, and one between receipt of
the NACM letter and the right to preferential treatment.
Following the suggestion by Therneau and Grambsch
periods in which a girl was not at risk (either because
the vaccine did not exist or because the girl was not eli-
gible for reimbursement) were treated as missing [6].
The results of our Cox regression are expressed in
Hazard Ratios (HR). A HR indicates the relative likeli-
hood of HPV vaccination initiation in two groups of
people with different values of a predictor at any given
point in time. It can also be interpreted as the likelihood
that a girl in the group with higher hazard initiates HPV
vaccination first [7], an interpretation that is intuitively
easier to understand.
Results
Descriptives
From January 1st 2007 until June 30th 2009 61,550 girls
(53%) out of our sample started with HPV vaccination.
Figure 2 shows the number of girls starting HPV vacci-
nation per month and per reimbursement regime. Three
periods can be discerned. During the first period (only
reimbursement via the Supplementary insurance) the
number of girls starting with HPV vaccination remained
relatively low. Then, when reimbursement via the Com-
pulsory insurance was introduced, this number spiked,
after which it very slowly decreased again. In this period
most of the vaccines were reimbursed under the Com-
pulsory insurance, but the number reimbursed under
the NACM Supplementary insurance also increased.
Finally, when the reimbursement under the Compulsory
insurance was extended to older girls, the number of
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Page 3 of 8girls starting HPV vaccination again spiked. Meanwhile
the Supplementary insurance gradually became
unnecessary.
Table 1 presents the number and percentage of girls
that had initiated HPV vaccination between January
2007 and June 2009 according to some (time constant)
background characteristics. We found a clear social
gradient, with girls having a right to preferential treat-
ment or living in a neighborhood with low median
income having a much smaller probability for having
started HPV vaccination. Further, vaccination uptake
slightly differed according to the province of residence.
Finally, there were large and significant differences in
vaccination initiation between girls of different years of
birth, with girls born in 1992 having the highest vacci-
nation uptake (82%) and girls born earlier or later hav-
ing gradually decreasing uptake percentages. To
interpret these differences, we had to take into account
the time varying reimbursement rules and the letter sent
by the NACM by means of a Cox regression model.
Cox regression model
Table 2 presents the results of the Cox regression.
Because the interaction between receipt of the NACM
letter and the right to preferential treatment was not
significant, it was not retained in the final model. We
advance four main findings:
First, girls eligible for reimbursement under the Com-
pulsory insurance had a substantially higher hazard of
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Figure 2 Number of girls starting HPV vaccination per month
and per reimbursement regime.
Table 1 HPV vaccination initiation according to background characteristics
Vaccination initiation
N (%)
No vaccination initiation
N (%)
P (chi square)
<0.0001
Year of birth 1989 3,081 (20.2) 12,202 (79.8)
1990 8,400 (53.4) 7,342 (46.6)
1991 8,270 (53.7) 7,118 (46.3)
1992 12,227 (81.9) 2,702 (18.1)
1993 10,758 (74.9) 3,615 (25.2)
1994 8,959 (65.2) 4,783 (34.8)
1995 6,690 (47.9) 7,278 (52.1)
1996 3,166 (23.1) 10,560 (76.9)
Preferential treatment <0.0001
Yes 1,816 (33.0) 3,692 (67.0)
No 59,735 (53.5) 51,908 (46.5)
Province <0.0001
Antwerp 16,369 (53.0) 14,537 (47.0)
Limburg 8,669 (57.2) 6,488 (42.8)
East-Flanders 13,466 (50.5) 13,210 (49.5)
West-Flanders 12,995 (49.0) 13,520 (51.0)
Flemish Brabant 10,052 (56.2) 7,845 (43.8)
Median income neighborhood
A <0.0001
Quintile1 7,103 (43.0) 9,404 (57.0)
Quintile2 11,301 (50.6) 11,019 (49.4)
Quintile3 12,411 (53.3) 10,868 (46.7)
Quintile4 14,240 (55.1) 11,598 (44.9)
Quintile5 16,496 (56.5) 12,711 (43.5)
A The quintiles are calculated for the whole of Flanders: each quintile encompasses 20% of all tax declarations in Flanders.
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bursement under the Supplementary insurance. Control-
ling for other factors, the hazard of starting HPV
vaccination under the strict Supplementary insurance
was only 9% of the hazard under the Complementary
insurance ([HR] = 0.09, 95% CI 0.09-0.09). The hazard
of starting HPV vaccination under the flexible Supple-
mentary insurance was even lower: only 1% of the
hazard under the Complementary insurance ([HR] =
0.01, 95% CI 0.01-0.01). For people with preferential
treatment this effect was stronger, as indicated by the
negative sign of the interaction between having a right
to preferential treatment and being eligible for Supple-
mentary insurance reimbursement.
Second, the hazard of HPV vaccination initiation was
higher for girls with a more favorable socio-economic
background. The hazard of HPV vaccination initiation
for girls with preferential treatment was only 55% of the
hazard for girls without preferential treatment ([HR] =
0.55, 95% CI 0.52-0.58). Likewise, the hazard differed
according to the median income of the neighborhood
where the girl was living.
Third, the hazard of HPV vaccination initiation was
higher for older girls. This is illustrated in figure 3 which
shows the hazard ratios for year of birth. The different
pattern for year of birth when considering vaccination
initiation percentages by June 30
th 2009 (table 1) or
hazard ratios (table 2 and figure 3) illustrates the fact that
hazard ratios do not directly relate to vaccination uptake.
The percentage girls that initiated HPV vaccination by
June 30
th 2009 (table 1) refers to the situation at one spe-
cific moment in time. This situation is the result of all
the girls having followed a certain trajectory over time
with continuously changing rates of HPV vaccination
initiation (hazard rates) depending on the values of the
predictors at each moment in time. The high uptake per-
centage of girls born in 1992 is mainly due to the fact
that girls in this age groupr e c e i v e dt h eN A C Ml e t t e r .
The lower uptake percentage of girls born in 1991 (and
before) compared to girls born in 1992 is mainly due to
the fact that they never had a right to reimbursement
under the Compulsory insurance. The lower uptake per-
centage of girls born in 1993 (and after) compared to
girls born in 1992 is mainly due to the effect of age.
Fourth, girls who were personally informed about the
Compulsory insurance reimbursement and the fact that
they were approaching the age limit had a substantially
higher hazard of HPV vaccination initiation ([HR] =
2.28, 95% CI 2.08-2.50).
Sensitivity analysis
By introducing a variable in the model that indicated
whether a girl had no, one or two or more sisters in the
Table 2 Cox regression model: Hazard of HPV vaccination
initiation
Hazard
ratio
95% CI
Year of birth
1989 19.39 17.47-21.52
1990 11.74 10.89-12.65
1991 4.32 4.11-4.55
1992 (base) - -
1993 0.61 0.55-0.67
1994 0.37 0.33-0.41
1995 0.21 0.19-0.24
1996 0.23 0.20-0.25
Province
Antwerp (base) - -
Limburg 1.13 1.10-1.16
West-Flanders 0.85 0.83-0.87
East-Flanders 0.88 0.86-0.90
Flemish-Brabant 1.00 0.98-1.03
Preferential treatment
No (base) - -
Yes 0.55 0.52-0.58
Median income neighborhood
Quintile 1 0.75 0.72-0.77
Quintile 2 0.93 0.90-0.95
Quintile 3 (base) - -
Quintile 4 1.04 1.02 -1.07
Quintile 5 1.10 1.07-1.12
Reimbursement regime
Compulsory (base) - -
Supplementary strict 0.09 0.09-0.09
Supplementary flexible 0.01 0.01-0.01
Letter NACM
No (base) - -
Yes 2.28 2.08-2.50
Preferential treatment (Yes) * NACM
reimbursement (strict or flexible)
0.55 0.47-0.64
0
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Figure 3 Cox regression model: hazard ratios with 95%
confidence intervals for year of birth illustrating the age-effect.
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Page 5 of 8same age group we tested whether having a sister
affected the vaccination behavior. Introducing this vari-
able did not significantly change the parameter estimates
of the other variables.
Discussion
The organization of HPV vaccination and local circum-
stances vary widely between countries, and so does HPV
vaccination uptake. Previous large-scale studies using
individual level data investigated HPV vaccination
uptake in an organized setting, be it through mass vacci-
nation sessions [8] or via school-based vaccination
[9-11]. We looked at HPV vaccination initiation in a
non-organized setting, whereby the initiative for vacci-
nation lied with the girls, their family or the gynecolo-
gist/pediatrician/general practitioner. We focused on
vaccination initiation and not on vaccination completion
(a complete regimen of the vaccine consists of 3 doses).
Note that of the 45,614 girls that started HPV vaccina-
tion before November 2008 (leaving them at least 9
months to complete the vaccine regimen within our
period of analysis, the recommended interval between
the first and the last dose being 6 months) 86% com-
pleted the regimen by June 2009.
There can be various reasons why the probability of
HPV vaccination was higher under the Compulsory
insurance as compared to the Supplementary insurance.
Most likely the generosity of the system played an
important role. The full price of the HPV vaccines was
130.22 euro per dose (3 doses required to be fully vacci-
nated). Under the Compulsory insurance, the reimburse-
ment was 119.42 euro per dose (123.02 euro for people
eligible for preferential treatment), leaving a co-payment
of 10.80 (7.20) euro per dose. Under the Supplementary
insurance, the reimbursement was only 50 euro per
dose (75 euro in case of preferential treatment). Redu-
cing out of pocket costs has been shown to improve
vaccination uptake for various children, adolescent and
adult vaccines [4,12-15]. In addition, the administrative
procedure of each of the reimbursement regimes might
also have been important. Under the Compulsory insur-
a n c et h eg i r lb u y i n gt h ev a c c i n eo n l yh a dt op a yt h e
non-refundable part of the price of the vaccine. Under
the Supplementary insurance the girl had to first
advance the full price of the vaccine, after which part of
it was refunded. Further, there was also substantially
more media attention and advertising (towards girls,
their families and medical doctors) for the Compulsory
insurance. These might have had an important influence
on the uptake of the vaccine: it has been shown that
mass media interventions can significantly affect various
health behaviors [16].
Vaccination uptake was substantially lower among
girls from lower socio-economic backgrounds. Such
association between socio-economic status and adoles-
cent vaccination has been found in other studies, too
[8,17-22]. Socio-economic differences in HPV vaccina-
tion uptake are particularly relevant since people with
low SES have a higher risk of contracting cervical cancer
[23,24]. An obvious explanation might be the financial
barrier caused by the co-payments [4,12-15]. However,
most likely other reasons have also played a role, such
as a differential influence of media attention on people
with different socio-economic backgrounds or advertis-
ing being more directed to certain categories of people.
Free, school-based HPV vaccination, as organized in
Flanders from September 2010 on, might help to over-
come this problem. School vaccination programs are
indeed considered as the best way to achieve good ado-
lescent vaccination uptake [15]. Evaluating the perfor-
mance of school vaccination programs in Flanders with
regard to socio-economic differences in vaccination
uptake however remains difficult: socio-economic differ-
ences are found for some of the vaccines currently
included in the school vaccination program, too, but
these might be partially attributed to differences in the
availability of documentation on vaccination at home,
since studies have to rely on documentation available at
home [25].
Older girls had a substantially higher probability of
vaccination initiation than younger girls. While these
findings are in line with recent findings from the US
[26], in the Netherlands a different relationship between
age and HPV vaccination has been found, with both the
oldest and the youngest age categories having a slightly
lower HPV vaccination uptake [8]. A possible explana-
tion for the age effect we found is an increased parental
acceptance of the vaccine as the age of the daughter
increases [27]. Another possible explanation is procrasti-
nation: if girls had a long period of eligibility for reim-
bursement before them, they might have been less
inclined to start with vaccination.
Finally, the letter by which girls were informed about
their eligibility for HPV vaccine reimbursement and
the approaching age limit had a large influence on
vaccination initiation. This is in line with previous
research in which patient reminder and recall systems
have been shown to significantly affect vaccination
behavior [28].
Conclusion
We studied determinants of HPV vaccination initiation in
Flanders (Belgium). Despite the fact that during our period
of analysis the initiative for vaccination lied with the girls,
their family or the gynecologists/pediatricians/general
practitioners (no organized setting), vaccination uptake
was high for certain subcategories of girls. However, large
socioeconomic differences were found. This suggests that
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in September 2010 (although with the possibility to refuse
the vaccine or to get vaccinated by a physician outside the
school-based system), might be preferred. Future research
could give more insight in the evolution of HPV vaccina-
tion uptake under this school-based system, as well as in
the factors underlying the observed socioeconomic
differences.
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